Elisa Antigen Test to Fast-pace India’s testing, monitoring, and Covid-19 management efforts

Elisa Antigen Test to Fast-pace India’s testing, monitoring, and Covid-19 management efforts


  • Post By :

  • Source: J Mitra & Company

  • Date: 22 Jun,2021

New Delhi; 22nd June 2021: India’s biotechnology leader in the IVD space, J Mitra and Company has launched the Covid-19 Ag Microlisa Elisa Test kit (Elisa Antigen Test) for the Indian market. The test kit will provide an impetus to India’s fight against Covid-19 by significantly bringing down the overall cost of testing. It will also offer better time efficiencies by reducing the turnaround time between testing and results to just 2 hours. The principle of the test kit is Sandwich Elisa. Any open Elisa kit Reader available in the market can read the results. Open-system will result in efficient testing even in the remotest corners of the country. The country already has thousands of Elisa readers with laboratories across the country.

 Elisa Antigen Test is as Reliable as RT-PCT
 Costs significantly lower than RT-PCR test
 Test-Result time Reduction to 2 hrs for 92 simultaneous tests
 Minimal Infrastructure Required; Can be managed by Small Labs
 J Mitra first Indian company to commercially produce this test
 Suitable for VTM ( Remote Collection) and non-VTM samples
 The Principle of the kit is Sandwich Elisa

About the Test
The Covid-19 Ag Microlisa Elisa Test kit is the first kit designed for the in-vitro qualitative detection of Covid-19 nucleocapsid antigen in nasal and oropharyngeal swabs and sample diluent. The Elisa Antigen Covid-19 test offers high Sensitivity & Specificity, and accuracy equivalent to RT-PCR tests. And it does this at costs that are comparable to Rapid tests. The combination of low cost, speed, and accuracy makes the Elisa Antigen Covid-19 Test kit a powerful solution for the diagnostic labs to fast-pace India’s comprehensive monitoring and detection process. All necessary approvals from ICMR and DCGI have been received.

Lalit Mahajan, chairman of J Mitra & Co said, “The Elisa antigen test is our 10th R&D based product in the fight against Covid-19. We are committed to the masses and will strive to help in the eradication of the disease.”

Taking about practical usages of the EAT, Jatin Mahajan, managing director of J Mitra & Co, said, “The Elisa Antigen test will help in management and mitigation of risks through quicker and reliable results – positive patients can be quickly isolated. For the masses, this test will minimise uncertainty and confusion due to prolonged delays in test results – to decide whether it is safe to interact or isolate and quarantine. We hope to majorly transform the testing and detection scenario with this path-breaking product.”

For further information, please contact:
Prasun Peter @ 9811279008, prasun.peter@gmail.com

About Author